Invasive Pneumococcal Disease Market Poised for Transformative Growth by 2034, Predicts DelveInsight | Pfizer, Merck, GlaxoSmithKline

Did you know the Invasive Pneumococcal Disease market is advancing rapidly? DelveInsight's latest 7MM report explores key epidemiology trends and market insights.
DelveInsight's "Invasive Pneumococcal Disease - Market Insight, Epidemiology, And Market Forecast - 2034 [https://www.delveinsight.com/report-store/invasive-pneumococcal-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr] report offers an in-depth understanding of the Invasive Pneumococcal Disease, historical and forecasted epidemiology as well as the Invasive Pneumococcal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Some of the key facts of the Invasive Pneumococcal Disease Market Report:

- According to DelveInsight, the market for Invasive Pneumococcal Disease (IPD) in the 7MM is expected to experience significant growth during the study period from 2020 to 2034.

- The incidence of invasive pneumococcal disease (IPD) is approximately 15.08 (95% CI 11.01-20.65) per 100,000 population in Spain, compared to 2.56 (95% CI 1.54-4.24) per 100,000 in Italy.

- Insights indicate that IPD incidence in 2022-2023, compared to 2019-2020, was 34% higher in children under 15 years of age, while it was 17% lower in adults aged 15 years and older.

- In January 2025, Vaxcyte's investigational 31-valent pneumococcal conjugate vaccine, VAX-31, received Investigational New Drug (IND) clearance from the FDA for infants. This vaccine aims to prevent invasive pneumococcal disease (IPD) in both infants and adults.

- In June 2024, Merck announced the FDA approval of CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine), designed for active immunization to prevent invasive disease caused by Streptococcus pneumoniae serotypes in individuals aged 18 and older.

- Emerging therapies in the field include GSK5101955, GSK5101956, GBP-410, and others.

- Key companies in the IPD market include Pfizer, Merck, Wyeth Pharmaceuticals, GlaxoSmithKline, Merck Sharp & Dohme Corp, Affinivax/Astellas Pharma, Vaxcyte, ImmunoBiology Ltd., EuBiologics, and others.

To Know in detail about the Invasive Pneumococcal Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Invasive Pneumococcal Disease Market Forecast [https://www.delveinsight.com/report-store/invasive-pneumococcal-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Invasive Pneumococcal Disease OverviewInvasive pneumococcal disease (IPD) is a serious condition caused by Streptococcus pneumoniae infections, often leading to severe complications and fatalities. It primarily affects young children and the elderly, with symptoms varying based on the site of infection and the individual's overall health. Common manifestations of IPD include pneumonia, acute otitis media (middle ear infection), meningitis (infection of the brain membranes), and bacteremia/sepsis, which can become life-threatening if not treated promptly.

Certain factors heighten the risk of developing pneumococcal infections, including asplenia or splenic dysfunction, chronic respiratory, heart, kidney (including post-transplant), and liver diseases, as well as diabetes managed with insulin or medications. Additionally, immunocompromised individuals face a significantly higher risk of severe infection.

Get a Free sample for the Invasive Pneumococcal Disease Market Report: https://www.delveinsight.com/report-store/invasive-pneumococcal-disease-market [https://www.delveinsight.com/report-store/invasive-pneumococcal-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Invasive Pneumococcal Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Invasive Pneumococcal Disease Epidemiology Segmentation:

The Invasive Pneumococcal Disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

- Total Incident Cases of Invasive Pneumococcal Disease

- Age-specific Incident Cases of Invasive Pneumococcal Disease

- Gender-specific Incident Cases of Invasive Pneumococcal Disease

- Treatable Cases of Invasive Pneumococcal Disease

Download the report to understand which factors are driving Invasive Pneumococcal Disease epidemiology trends @ Invasive Pneumococcal Disease Epidemiology Forecast [https://www.delveinsight.com/report-store/invasive-pneumococcal-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Invasive Pneumococcal Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Invasive Pneumococcal Disease market or expected to be launched during the study period. The analysis covers the Invasive Pneumococcal Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Invasive Pneumococcal Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Invasive Pneumococcal Disease Market Strengths

- Widespread immunization initiatives, such as pneumococcal conjugate vaccines (PCVs), have significantly reduced disease incidence, driving market stability and continued demand for preventive measures.

- Ongoing research and innovation in next-generation vaccines and antibiotic therapies enhance treatment efficacy and expand market potential.

Invasive Pneumococcal Disease Market Weaknesses

- The rising prevalence of drug-resistant Streptococcus pneumoniae strains poses a major challenge, limiting treatment options and increasing disease burden.

- The cost of pneumococcal vaccines and advanced therapies remains a barrier, particularly in low- and middle-income countries, restricting widespread accessibility and adoption.

Scope of the Invasive Pneumococcal Disease Market Report

- Study Period: 2020-2034

- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

- Key Invasive Pneumococcal Disease Therapies: GSK5101955, GSK5101956, GBP-410, and others.

- Key Invasive Pneumococcal Disease Companies: Pfizer, Merck, Wyeth Pharmaceuticals, GlaxoSmithKline, Merck Sharp & Dohme Corp, Affinivax/Astellas Pharma, Vaxcyte, ImmunoBiology Ltd., EuBiologics, and others.

- Invasive Pneumococcal Disease Therapeutic Assessment: Invasive Pneumococcal Disease currently marketed and Invasive Pneumococcal Disease emerging therapies

- Invasive Pneumococcal Disease Market Dynamics: Invasive Pneumococcal Disease market drivers and Invasive PneumococcalDisease market barriers

- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

- Invasive Pneumococcal Disease Unmet Needs, KOL's views, Analyst's views, Invasive Pneumococcal Disease Market Access and Reimbursement

To learn more about the key players and advancements in the Invasive Pneumococcal Disease Treatment Landscape, visit the Invasive Pneumococcal Disease Market Analysis Report [https://www.delveinsight.com/report-store/invasive-pneumococcal-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Table of Contents

1. Invasive Pneumococcal Disease Market Report Introduction

2. Executive Summary for Invasive Pneumococcal Disease

3. SWOT analysis of Invasive Pneumococcal Disease

4. Invasive Pneumococcal Disease Patient Share (%) Overview at a Glance

5. Invasive Pneumococcal Disease Market Overview at a Glance

6. Invasive Pneumococcal Disease Disease Background and Overview

7. Invasive Pneumococcal Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Invasive Pneumococcal Disease

9. Invasive Pneumococcal Disease Current Treatment and Medical Practices

10. Invasive Pneumococcal Disease Unmet Needs

11. Invasive Pneumococcal Disease Emerging Therapies

12. Invasive Pneumococcal Disease Market Outlook

13. Country-Wise Invasive Pneumococcal Disease Market Analysis (2020-2034)

14. Invasive Pneumococcal Disease Market Access and Reimbursement of Therapies

15. Invasive Pneumococcal Disease Market Drivers

16. Invasive Pneumococcal Disease Market Barriers

17. Invasive Pneumococcal Disease Appendix

18. Invasive Pneumococcal Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=invasive-pneumococcal-disease-market-poised-for-transformative-growth-by-2034-predicts-delveinsight-pfizer-merck-glaxosmithkline]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.